Jeffrey Draluck, MD
Dermatology · Northbrook, IDNPI 1417066911
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,043 of the $35,579 with a category attached, or 81.6%. AbbVie accounts for 84.1% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2021 at $11,366 and has fallen 73.3% since, to $3,030 in 2025. Among dermatology clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 386 payments — averaging $92.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Sanofi$676
- Regeneron Healthcare Solutions, Inc.$666
- Pfizer$489
- Dermavant Sciences, Inc.$478
- Johnson & Johnson$353
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$29,04382%
- Food & beverage$6,53718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 105 | $29,936 |
| Sanofi | 24 | $676 |
| Regeneron Healthcare Solutions, Inc. | 24 | $666 |
| Pfizer | 35 | $489 |
| Dermavant Sciences, Inc. | 32 | $478 |
| Johnson & Johnson | 14 | $353 |
| Novartis | 16 | $352 |
| Amgen | 14 | $315 |
| Sun Pharmaceutical Industries Inc. | 13 | $258 |
| Incyte Corporation | 11 | $255 |
| UCB, Inc. | 9 | $249 |
| Lilly USA, LLC | 13 | $248 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 13 | $239 |
| Galderma Laboratories, L.p. | 16 | $234 |
| E.r. Squibb & Sons, L.L.C. | 11 | $197 |
| Biofrontera Inc. | 5 | $80 |
| Organon | 4 | $68 |
| Mayne Pharma Commercial LLC | 3 | $55 |
| EPI Health, LLC | 3 | $44 |
| Arcutis Biotherapeutics, Inc. | 2 | $42 |
| Botanix SB Inc | 2 | $41 |
| Fresenius Kabi USA, LLC | 2 | $35 |
| Genentech USA, Inc. | 2 | $30 |
| Merck | 2 | $27 |
| Verrica Pharmaceuticals Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $25 |
| Bristol Myers Squibb | 1 | $23 |
| Organogenesis Inc. | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $22 |
| Dermira, Inc. | 1 | $19 |
| DUSA Pharmaceuticals, Inc. | 1 | $18 |
| Almirall LLC | 1 | $15 |
| Aclaris Therapeutics, Inc. | 1 | $15 |
| LEO Pharma Inc. | 1 | $14 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$131
How this compares
$35,579 in reported general payments places this provider in the 90th percentile of 52 dermatology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $79,217 |
| EliquisApixaban | 11 | $6,326 |
| Clobetasol Propionate | 69 | $2,517 |
| Metronidazole | 25 | $1,344 |
| Triamcinolone Acetonide | 180 | $1,127 |
| Ketoconazole | 89 | $1,067 |
| Fluorouracil | 12 | $1,022 |
| Fluocinonide | 21 | $832 |
| Clindamycin Phosphate | 39 | $586 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 22 | $480 |
| Econazole Nitrate | 20 | $401 |
| Cephalexin | 14 | $326 |
| ValacyclovirValacyclovir Hcl | 14 | $283 |
| Spironolactone | 16 | $271 |
| Minoxidil | 13 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $489 | $6,32611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 52 dermatology providers in Idaho.
Other dermatology in Northbrook
- Alan OlmsteadTwin Falls$405K
- Dustin PortelaBoise$164K
- Steven MingsBoise$82K
- Ryan HarrisMeridian$58K
- Mark SchwendimanMeridian$9K
- Ryan OwsleyNampa$9K
- Kelsey FerrellMeridian$6K
- Nicholas BlickenstaffBoise$6K
- Randall BurrMeridian$5K
- Ted RyserNampa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.